Taken together, Gal-3C might be a specific competitive motif to inhibit endogenous full-length Gal-3, which drove us to suppose that further modification of Gal-3C could generate novel fusion proteins with better anti-tumor activity. The gene discussed is GAL; the disease is neoplasm.